Navigation Links
$89 Million Proposed Class Action Settlement Provides Consumers and Insurers With Money Back for Celebrex and Bextra Purchases and Reimbursements
Date:4/29/2009

WASHINGTON, April 29 /PRNewswire-USNewswire/ -- A federal court in San Francisco has granted preliminary approval to a proposed settlement with Pfizer Inc. ("Pfizer") about the marketing of the prescription drugs Bextra and Celebrex. The settlement in the case called In re Bextra and Celebrex Marketing, Sales Practices, and Product Liability Litigation, No. 05-CV-01669, MDL No. 1699, pending in the United States District Court for the Northern District of California, will provide a Settlement Fund of $89 million to benefit a class of consumers and insurance companies or other entities (also called Third-Party Payors) that paid for either medicine before July 29, 2005.

The lawsuit, which does not concern safety risk of either drug, claims that Pfizer falsely advertised Bextra and Celebrex as having greater benefits than less expensive pain medications, causing consumers and other entities to pay a greater price for Bextra and Celebrex than they would otherwise have paid for less expensive alternatives or no medications at all. The lawsuit also claims that the advertising was not consistent with the drugs' Food and Drug Administration approved labeling. Pfizer denies any wrongdoing and denies all of the claims in the lawsuit but is settling this lawsuit to avoid the cost and expense of further litigation.

Consumers who paid for Bextra and/or Celebrex on or before July 29, 2005 are included in the Proposed Settlement. Third-Party Payors that paid or reimbursed for all or a percentage of the cost of Bextra and/or Celebrex on or before July 29, 2005 can also make a recovery under the Proposed Settlement. Third-Party Payors include insurance companies, union health and welfare plans, and self-insured employers.

Consumers and Third-Party Payors that wish to remain in the Settlement and file a claim will be bound by the Court's orders and will give up the right to sue the defendants on their own. Claim forms must be postmarked by October 23, 2009.

The Court will hold a Final Approval Hearing on September 25, 2009 at 10 a.m. to consider whether the Proposed Settlement is fair, reasonable, and adequate and the motion for attorneys' fees and expenses. For more information, including a claim form, Class Members may call toll-free 1-800-547-9360, visit www.BextraCelebrexSettlement.com, or write: Bextra and Celebrex Claims Administrator, c/o Rust Consulting, Inc., P.O. Box 24675, West Palm Beach, FL 33416.


'/>"/>
SOURCE Bextra and Celebrex Claims Administrator
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Registered Organ Donors Near Five Million, Save 300 Lives Since 2006
2. Kaiser Permanente Approves $13 Million in Community Benefit Grants in First Quarter of 2009
3. FSU researcher wins $2.2 million grant to study childhood obesity
4. UN Foundation to Help Protect More than a Million Refugees from Malaria in Africa
5. Treatment Options Increase For Millions with Fibromyalgia
6. Attorney General Eric Holder Honors Florida Doctor and Announces $4.7 Million in Recovery Act Funds for State
7. Neovasc Completes $2 Million Non-Brokered Private Placement
8. Working Towards Counting Malaria Out Through Scale-Up of PermaNet(R) Bed Nets, Vestergaard Frandsen Produces 175 Millionth Net; Introduces New Net To Combat Insecticide Resistance
9. Millions of Youth Around the World Volunteer to Improve Communities
10. Proposed $350 Million Class Action Settlement Regarding Drug Pricing Provides Consumers and Third-Party Payors With Money Back
11. The Female Health Company / HLL Lifecare Limited Receive National AIDS Control Organization of India Order for 1.5 Million FC2 Female Condoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 08, 2016 , ... According to research by the National ... technicians to be certified or obtain continuing education. To increase patient awareness of ... Your Mouth?” campaign to inform dentists and patients about the possible lack of ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. announced today ... the tools and information to lower the costs, and increase the impact of ... providing employee healthcare benefits by as much as 22%:, + Price and ...
(Date:2/6/2016)... ... ... US Sports Camps is proud to sponsor the Bay Area Disc Association's ... leaders, ultimate organizations, and coaches from around the US. The theme for this year’s ... of Youth and Education, describes this year YUCC as “an important conversation we must ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... eating disorder treatment helps to reduce the frequency and level of relapse. ... Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks of the ...
(Date:2/5/2016)... ... 2016 , ... VeloReality President and co-founder Gary ... VR Indoor Trainer with multi-rider capability to an enthusiastic audience at the company's ... the weight of the unit, they also enhance the rider's experience with a ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 2016 Vestagen Technical Textiles, Inc., a medical ... healthcare and other demanding applications, today announced it has ... replaces Dale Pfost , PhD, who was serving ... also joining Vestagen,s Board of Directors. ® ... barrier technologies that combines fluid repellent, antimicrobial and breathability ...
(Date:2/8/2016)... Ill. , Feb. 8, 2016  Astellas Pharma Inc. ... announced the promotion of James Robinson as president, ... company,s operations in North and South America ... Astellas Pharma US, representing the commercial organization in ... in 2013. Masao Yoshida , who is ...
(Date:2/8/2016)... , Feb. 8, 2016  CTI BioPharma Corp. ... Company received written communication from the U.S. Food and ... FDA has placed a partial clinical hold on the ... Drug ("IND") application for pacritinib. This clinical hold impacts ... the IND and will also affect planned clinical trials. ...
Breaking Medicine Technology: